Metsera (NASDAQ:MTSR) Earns Outperform Rating from Analysts at Evercore ISI

Evercore ISI initiated coverage on shares of Metsera (NASDAQ:MTSR) in a research note issued to investors on Tuesday, MarketBeat reports. The brokerage issued an outperform rating on the stock.

Metsera Stock Performance

Shares of NASDAQ MTSR opened at $25.01 on Tuesday. Metsera has a 12-month low of $24.70 and a 12-month high of $32.81.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.